Pharma Sector Mein Tension Hi Tension! **29** Vitamin/Mineral Drugs Par Regulator Ki Nazar, Ban Ho Sakta Hai?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Pharma Sector Mein Tension Hi Tension! **29** Vitamin/Mineral Drugs Par Regulator Ki Nazar, Ban Ho Sakta Hai?
Overview

Dekho yaar, India ke drug regulators ne ek aur chakkar shuru kar diya hai! Ab woh **29** aise Fixed-Dose Combination (FDC) drugs, jo mostly vitamin aur mineral wale hain, unko check kar rahe hain. Point yeh hai ki inke 'therapeutic justification' matlab, dawa dene ka sahi reason hai bhi ya nahi, is par shaq hai. Is wajah se inko band bhi kiya ja sakta hai. Pharma sector ke liye toh yeh ek aur 'regulatory headache' ban gaya hai.

Kya Hai Yeh Naya Mamla? (The New Story)

Toh bhai, yeh 29 FDCs pe jo scrutiny chal rahi hai, yeh kuch naya nahi hai. Pehle bhi 2015 mein ek expert panel ne inko 'irrational' bola tha. Ab case Dr. Nilima Kshirsagar ki ek sub-committee ke paas hai, jo companies ko sunegi aur phir final decision legi. Basically, regulator chahte hain ki har dawa ka ek solid reason ho market mein rehne ka.

Yeh FDC Ka Pura Kissa Kya Hai? (The Whole FDC Saga)

India mein FDCs ka scene hi aisa hai. 2016 mein 344 FDCs ko ban kiya gaya tha. Phir Supreme Court ne beech mein pad kar kaha ki DTAB phir se review kare. Abhi August 2024 mein 156 aur April 2025 mein 35 FDCs ko ban kiya gaya hai. Problem yeh hai ki pehle state drug authorities aasani se license de dete the, jisse hazaron illogical combinations market mein aa gayin.

Market Par Kya Padega Asar? (Market Impact)

FDC segment toh India ke pharma market ka lagbhag 40% se 50% hissa hai. Sirf vitamin aur mineral wale segment ki market bhi kaafi badi hai. Jab 2016 mein 344 FDCs ban hue the, toh Marksans Pharma, Wockhardt, Pfizer jaise companies ke shares 20% se 55% tak gire the! Is baar 29 drugs hain, toh impact chhota nahi ho sakta. Companies ko ab R&D aur asli innovation pe focus karna padega. Sun Pharma, Cipla, Dr. Reddy's jaise bade players is game mein hain.

Kya Hai Pharma Companies Ke Liye Risk? (Risks for Pharma Companies)

Sabse bada tension toh 'regulatory uncertainty' ka hai. Kab kya ban ho jaaye, kuch pata nahi. Agar yeh drugs band hue toh revenue ka nuksaan pakka hai. Aur compliance ka burden bhi badh jayega, matlab solid data dena padega ki dawa kaam ki hai. Ek aur chinta hai ki antibiotic FDCs se Antimicrobial Resistance (AMR) badh raha hai.

Aage Kya Hoga? (Future Outlook)

Pharma sector ek naye mod par hai. Ab 'evidence-based' drugs aur 'rational' combinations pe hi zor chalega. Companies ko R&D mein invest karna hoga aur global standards follow karne honge. Regulator chahte hain ki public health aur safety top par rahe. Yeh FDC market ko theek karna ek lambi race hai, par kadam toh uth rahe hain.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.